Australia markets open in 9 hours 59 minutes
  • ALL ORDS

    7,280.60
    +49.60 (+0.69%)
     
  • AUD/USD

    0.7697
    +0.0050 (+0.65%)
     
  • ASX 200

    7,023.10
    +46.20 (+0.66%)
     
  • OIL

    61.50
    +1.32 (+2.19%)
     
  • GOLD

    1,737.70
    -9.90 (-0.57%)
     
  • BTC-AUD

    83,093.12
    +693.77 (+0.84%)
     
  • CMC Crypto 200

    1,373.57
    -2.21 (-0.16%)
     

Spasticity Epidemiology Forecast to 2030: Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan - ResearchAndMarkets.com

·4-min read

The "Spasticity - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This 'Spasticity - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Spasticity, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Spasticity Epidemiology

The Spasticity epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total prevalent cases of Spasticity patients are increasing in 7MM during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Spasticity symptoms epidemiology segmented as the Prevalent Population of Spasticity, Gender-Specific Spasticity Prevalence, and Spasticity prevalence by causes. The report includes the prevalent scenario of Spasticity symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise - Spasticity Epidemiology

The epidemiology segment also provides the Spasticity epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent cases of Spasticity associated in 7MM countries were 4,481 in 2020.

  • As per the estimates, the United States has the largest prevalent population of Spasticity.

  • Among the EU5 countries, Germany had the highest prevalent cases of Spasticity, followed by Italy. On the other hand, Spain had the lowest incident cases, with 227 cases in 2020 in EU5.

Scope of the Report

  • The Spasticity report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.

  • The Spasticity Epidemiology Report and Model provide an overview of the risk factors and global trends of Spasticity in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

  • The report provides insight into the historical and forecasted patient pool of Spasticity in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.

  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.

  • The report assesses the disease risk and burden and highlights the unmet needs of Spasticity.

  • The report provides the segmentation of the Spasticity epidemiology by gender-specific spasticity prevalence in 7MM.

  • The report provides the segmentation of the Spasticity epidemiology by spasticity prevalence by different causes in 7MM.

Report Highlights

  • 11-year Forecast of Spasticity epidemiology

  • 7MM Coverage

  • Prevalent Cases according to segmentation: Gender-Specific Spasticity Prevalence

  • Prevalent Cases according to segmentation: Spasticity Prevalence by different causes

KOL Views

We interview KOLs, and SME's opinion through primary research to fill the data gaps and validate the secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM for the patient population of Spasticity?

  • What are the key findings of the Spasticity epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?

  • What would be the total number of patients of Spasticity across the 7MM during the forecast period (2017-2030)?

  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?

  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?

  • What are the disease risk, burdens, and unmet needs of the Spasticity?

  • What are the currently available treatments of Spasticity?

Key Assessments

  • Patient Segmentation

  • Disease Risk and Burden

  • Risk of disease by the segmentation

  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States

  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)

  • Japan

For more information about this report visit https://www.researchandmarkets.com/r/5fvqr3

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005525/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900